CMS and FDA Unveil RAPID Pathway to Accelerate Medicare Coverage for Breakthrough Devices

The Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) have launched the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway to streamline the transition from regulatory authorization to reimbursement. This initiative aims to reduce the coverage gap for designated Class II and Class III breakthrough medical devices from over a year to as little as two months. By aligning evidence requirements between the two agencies, the program seeks to provide Medicare beneficiaries with faster access to life-saving technologies while reducing administrative hurdles for manufacturers.

The RAPID pathway facilitates early collaboration between the FDA, CMS, and device manufacturers during the development process to ensure clinical trials meet the evidentiary standards of both agencies. Under this framework, the CMS will issue a proposed national coverage determination (NCD) on the same day a qualifying device receives FDA marketing authorization, triggering a 30-day public comment period. This proactive approach allows manufacturers to design pivotal trials that capture clinical outcomes relevant to Medicare beneficiaries, potentially avoiding the need for secondary trials that have historically delayed coverage by an average of five years post-authorization according to data from Stanford and Duke-Margolis.

To qualify for the RAPID pathway, products must be designated as breakthrough devices that address unmet clinical needs for the Medicare population. The program is open to Class III devices and certain Class II devices participating in the FDA’s Total Product Life Cycle Advisory Program (TAP), provided they are subject to an investigational device exemption (IDE) study that enrolls Medicare beneficiaries. CMS officials indicated that approximately 40 devices currently qualify for the pathway, with another 20 potentially eligible in the near future. Notably, the CMS will pause the existing Transitional Coverage for Emerging Technologies (TCET) pathway—which was criticized for being limited to only five devices per year—to focus resources on the broader RAPID initiative.

Leadership from both agencies, including FDA Commissioner Marty Makary and CMS Administrator Dr. Mehmet Oz, emphasized that the partnership aims to cut red tape and function as a single team to deliver innovation to patients. While the medical device lobby group AdvaMed welcomed the announcement as a positive step, CEO Scott Whitaker cautioned that the program’s success depends on effective management, accountability, and meaningful timelines to ensure patients see the full benefits. The proposal will now undergo a 60-day public comment period following its publication in the Federal Register, as the industry looks for more certainty in the reimbursement landscape for high-risk, high-impact medical technologies.